The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world analysis of irinotecan (iri) with or without fluorouracil (5FU) in the second line treatment (2L) of metastatic colorectal cancer (mCRC).
 
Robert William Lentz
Consulting or Advisory Role - Myeloid Therapeutics (Inst)
Research Funding - ALX Oncology (Inst); Guardant Health (Inst); Lilly (Inst); Merck (Inst)
 
Junxiao Hu
No Relationships to Disclose
 
Hannah Ruth Robinson
No Relationships to Disclose
 
Nicole Baranda Balmaceda
No Relationships to Disclose
 
Emily Eyoung Baiyee Ebot
No Relationships to Disclose
 
Alexis Diane Leal
Employment - Elsevier
Leadership - Elsevier
Research Funding - Abbvie (Inst); Arrys Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conjupro Biotherapeutics (Inst); Corcept Therapeutics (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Hutchison MediPharma (Inst); Takeda (Inst)
 
Sunnie S. Kim
Honoraria - Merck
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo/Lilly; I-Mab
Research Funding - Merck
 
S. Lindsey Davis
Stock and Other Ownership Interests - Johnson & Johnson/MedTech
Speakers' Bureau - Allergan (I)
Research Funding - Boston Scientific (I); Bristol-Myers Squibb (Inst); EMD Serono (Inst); I-Mab (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Symphogen (Inst); TriSalus Life Sciences (Inst); Tvardi Therapeutics (Inst)
 
Wells A. Messersmith
Honoraria - Research to Practice (Inst)
Consulting or Advisory Role - Amgen; Criterium (Inst); QED Therapeutics; Zymeworks
Research Funding - ALX Oncology (Inst); Beigene (Inst); CanBas (Inst); D3 (Inst); Exelixis (Inst); FATE Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); RasCal (Inst)
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Pfizer (Inst)
Research Funding - Merck (Inst)